Close Menu

Waters

These designations mean the system can be sold in the US and Europe for use in laboratory-developed tests including, for instance, protein-based diagnostics.

The company posted revenues of $500.6 million, up from $493.2 million in Q3 2014. Currency effects contributed to a roughly 7 percent reduction in sales growth.

Overall, analyst Bryan Brokmeier said he is bullish on the space in spite of uncertainty in the general global markets.

The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.

The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.

Waters has signed an instrument control agreement with Agilent and recognized Chang Gung University as a Center of Innovation Partner.

The conference was relatively light on new mass spec launches, with many vendors focusing instead on more targeted applications of existing technology.

The company posted revenues of $460.4 million compared to $430.5 million in Q1 2014, beating the average Wall Street estimate of $445.3 million.

The amendment to a 2013 debt financing agreement will increase revolving commitments to $1.3 billion, extend maturity of loans, and adjust interest rates and fees.

Interest in detection directly from specimens and antibiotic resistance is leading some researchers to look at methods likeREIMSand MRM-MS.

Pages

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.